| INTRODUCTION
The most frequent complication of transradial catheterization (TRA) is radial artery occlusion (RAO). Estimated to occur in 5-10% of cases, it limits future utility of the radial artery as an access site for angiographic and therapeutic procedures.
1, 2 The following factors have been identified as independent predictors in the majority of studies: the diameter of the sheath and its relationship to the size of the radial artery, postprocedure compression time, and the presence of anterograde flow in the artery during hemostasis.
compression needed to achieve hemostasis may presumably also be of help in reducing the occurrence of RAO. The RAO rate with patent hemostasis achieved by TR Band (Terumo medical) is around 5% with the band left in place for 2 h. has been shown to produce local hemostasis by acting topically after major arterial vessel injury. 10, 11 Reducing the compression time during patent hemostasis by facilitating hemostasis may decrease RAO. To test this hypothesis, we planned a three arm randomized study to evaluate the safety and efficacy of ABS in adjunct to short-time compression, compared to either short-time compression with conventional sterile gauzes (CSG) or with a TR band after transradial procedures.
| METHODS AND ANALYSIS
The Ankaferd blood stopper as a New Strategy to Avoid Early Barbeau's test 12 before puncture and failure to provide written informed consent. The patients were randomized into three arms corresponding to three different strategies of patent hemostasis techniques after diagnostic or interventional catheterization. Randomization was done using a block design in order to ensure that the same number of patients would be assigned to each group. All procedures were performed by two interventional cardiologists at a single center. The protocol was approved by the institutional review board and written informed consent was provided by all patients.
After sterile preparation and injection of 2% prilocaine at the puncture site, a 20-gauge open bore needle was used to enter the radial artery 1-1.5 cm proximal to the radial styloid process. Observing a pulsatile flow, a 0.025″ straight guidewire was advanced. The needle was removed and a 6F short (7 cm) hydrophilic sheath (Radiofocus Introducer II, Terumo, Tokyo, Japan) was introduced over the guidewire. After sheath insertion, vasodilator (200 μg nitroglycerin) was given and subsequently 5000 IU of unfractionated heparin diluted in a 10-mL syringe was injected into the aortic arch. Radial artery angiogram was obtained just after sheath insertion in order to measure the radial artery diameter angiographically. After radial arteriography, off-line quantitative analysis was used to determine radial artery diameter. Diagnostic angiography was performed using diagnostic standard 6F Judkins catheters. Additional 5000 IU of unfractionated heparin was administered in case of an ad hoc interventional procedure. The unfractionated heparin dose given in elective interventional procedures was 10 000 IU. Before the radial sheath was removed at the end of the procedure, patients were allocated into one of the following hemostasis groups. ABS group: the compression of radial artery was obtained with ABS hemostatic pad applied directly on the skin with a folded gauze over the pad. All the dressing was then wrapped with an elastic bandage so that patent hemostasis is maintained. The patent hemostasis of the radial artery was assessed using reverse Barbeau's test as previously defined. 7 If there was no radial artery patency the elastic bandage was loosened till plethysmo- using reverse Barbeau's test as previously defined. 7 A pulse oximeter sensor was placed over the index finger and both radial and ulnar arteries were compressed to observe a loss of the plethysmographic signal. After the signal disappeared, the radial artery was released and the presence of the signal was assessed. Return of the signal indicated radial artery patency and the absence of return of the signal indicated RAO. All findings of occlusion were confirmed ultrasonographically by another investigator. Local hematomas were graded according to a specific scale 13 and hematomas larger than ≥5 cm were considered significant at 24 h after the procedure.
| Data collection
All findings, including clinical and laboratory data, were documented in the subjects medical record.
| Statistical analysis
Quantitative variables were presented as means (±standard deviation), and categorical variables were indicated as the absolute number (percentage). Data were tested for normal distribution using the 
| Ethical considerations
The study was performed in agreement with the Declaration of Baseline data for the three groups is presented in Table 1 . Baseline characteristics were similar in both groups. No significant difference was observed in height, weight, antiplatelet, and anticoagulant treatment between the groups (P > 0.05).
Clinical and procedural characteristics such as acute coronary syndrome, previous radial puncture, radial artery anomaly, radial artery diameter, procedural time were not different among the groups (Table 2) . While the need for manual compression was less in the ABS group (P < 0.001), the ABS group and CSG group experienced more pain compared to the TR Band group after the first 24 h (P = 0.001).
Results of outcome measures are shown in Table 3 As shown in Table 3 Logistic regression analysis was performed on all variables for the bleeding complication (Table 4) . Age, weight, height, chronic clopidogrel therapy, heparin dose were included into the multivariate logistic regression model because of their unadjusted P values were <0.05. Heparin dose (OR: 3.120 95% CI: 2.052-4.743, P < 0.001), height (OR: 1.034 95% CI: 1.006-1.063, P = 0.019), weight (OR: 1.021 95% CI: 1.004-1.039, P = 0.018), and chronic clopidogrel therapy (OR:
1.615 95% CI: 1.009-2.586, P = 0.046) were found as the independent predictors of bleeding.
| DISCUSSION
The main result of our study is that with patent hemostasis by using ABS it is possible to totally avoid RAO and ABS is very effective in preventing bleeding complications at the end of patent hemostasis.
Despite conventional patent hemostasis with dedicated devices such as TR Band, the contemporary "real-world" incidence of RAO reported from institutions with expertise in performing TRA continues to reach 10%. 14 Knowing that reducing the duration of compression from 6 to 2 h, reduces the incidence of RAO, 15 we tested the hypothesis reducing the compression time even further with the help of ABS which might cause even less RAO rates.
Interestingly, none of our study patients had RAO at 30-day followup. One of the lowest RAO achieved at 30-day was revealed in the PROPHET-II Trial with a 3% RAO using conventional patent hemostasis with TR Band and a 0.9% RAO rate in the group of simultaneous ipsilateral ulnar artery transient compression. 16 Recently, Koutouzis et al defined ipsilateral ulnar artery transient compression for facilitating radial artery patent hemostasis as the ULTRA method which reached a 0% RAO rate at the end of the patent hemostasis. 17 The conventional TR Band scored a 5% RAO whereas the RAO rate was %13.9 at the end of hemostasis in the PROPHET-II study. In our study the ABS group showed no RAO while the other groups had one patient with RAO in each group. In terms of RAO all groups in our study showed excellent results as similar as to those with the ULTRA method. It is hard to explain our %0 RAO rate at 30-day, because all of our study population underwent procedures with 6F sheaths and 118 patients had at least their second procedure at the same radial artery which both factors are known to increase the RAO rate. 18, 19 Our low RAO rates in all groups need explanation. First, patent hemostasis was achieved in 99.5% of our study patients and even during manual compression due to rebound bleeding which may eventually lead to revengeful pressure and RAO. Second, the interventions were performed by two radial operators who are experienced. Additionally, the nursing team handling the patients was also familiar with this method for a long period. Third, patients under NOAC (n = 8) and warfarin therapy (n = 18) alongside with 239 patients getting additional 5000 U of heparin (PCI + adhoc PCI) were not excluded from the study which may have decreased the RAO further down to 0.32% for all the study population at the end of the hemostasis. Finally, trying to relate the very low RAO rate (0.48%) to any reason in our conventional TR Band group, the study from Dangoisse et al was very enlightening. 20 In this paper, they reached a 0.6% RAO rate at 24 h when their used only 10 cc volume of air for the TR Band patent hemostasis.
Likewise, the average volume of air used in our TR Band group was 10.5 cc.
In accordance with our 0% RAO rate in the ABS group, another hemostatic pad named as the QuickClot indicated no RAO occurrence at 24 h. 21 However, the rebound bleeding rate (20%) was two times greater than our bleeding rate with ABS (9.40%) after the removal of the closure dressings. In a very recent pilot study with totally 30 patients included, successful hemostasis was achieved in 100% of patients with both the 30-and 60-min compression groups (in which the compression time was increased two-to fourfold compared to the first QuickClot study) using the QuikClot pad with no RAO. 22 Hemostasis failure occurred in 50% of patients when the TR Band was initially weaned at the protocol-driven time. 22 In our conventional patent hemostasis with TR Band hemostasis failure was 27.31%, and 
| LIMITATIONS
All procedures in our study were performed by experienced operators and patent hemostasis was achieved by a experienced nursing team.
Therefore, the observed results may not be applicable to less experienced centers. Second, this trial has originated from one center, with only two operators. Third, needed sample size was not assessed before trial, but the recruited subjects were at least outnumbering the similar studies. 
| CONCLUSION
ABS is promising for use in patent hemostasis during TRA, with no incidence of short-term or long-term RAO and with remarkable reduced risk of re-bleeding at the end of hemostasis.
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